AML Characterization by Flow Cytometry Immunophenotyping (Leukemia Diagnostic Panel) Test
Test Price
2,000 AEDโ Home Collection Available
AML Characterization by Flow Cytometry Immunophenotyping (Leukemia Diagnostic Panel) in UAE
Clinical Trust & Core Metrics
- โ 99.9% Diagnostic Sensitivity โ ISO 9001:2015 accredited processing with advanced 10-color flow cytometry.
- โ Hospital Extraction Only โ Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- โ Clinical Guidance โ Telephonic post-test clinical interpretation support by a DHA-licensed specialist.
- โ Insurance โ Direct billing verification via WhatsApp at +971 54 548 8731.
Executive Summary & Core Metrics
This DHA-approved flow cytometry panel delivers same-day, high-resolution immunophenotyping on bone marrow aspirate or peripheral blood, enabling precise AML subtyping and minimal residual disease monitoring. The test uses a 10-color, โฅ30-marker panel to classify blast populations, detect aberrant antigen expression, and guide risk-stratified therapy. Results are correlated with morphology, cytogenetics, and clinical presentation to ensure diagnostic accuracy.
Test Overview & Methodology
Flow cytometry immunophenotyping measures surface and cytoplasmic antigens on hematopoietic cells using laser-based multi-parameter detection. Our ISO-accredited protocol employs a comprehensive panel of lineage-defining markers โ including CD13, CD33, CD34, CD117, HLA-DR, MPO, CD14, CD64, CD7, CD56, and others โ to accurately differentiate AML from other acute leukemias and to identify specific WHO subtypes. The assay achieves high sensitivity for both diagnostic and post-therapy minimal residual disease assessment.
| Feature | Our Test (AML Characterization Panel) | Closest Alternative |
|---|---|---|
| Precision / Markers | 10-color flow cytometry with โฅ30 surface and cytoplasmic markers | Standard 4-6 color panel, limited markers |
| Method | ISO-accredited multi-parameter flow cytometry with cold-chain transport | Routine flow cytometry without cold-chain optimization |
| Turnaround Time | Same-day report (sample received by 9 AM) | 2-3 working days |
Physician Insight & Safety Protocols
"As a DHA-registered Specialist Diagnostic Radiologist, I emphasize that no single laboratory result defines a diagnosis. This immunophenotyping panel must be integrated with bone marrow morphology, cytogenetic analysis, and the patient's full clinical context. I urge clinicians and patients to treat these findings as a compass for therapy โ not as a standalone verdict โ and to maintain transparent dialogue with the treating hematologist."
โ Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Critical Advisory โ Medication Safety
Do not discontinue or alter any prescribed medication โ particularly chemotherapy or targeted agents โ without direct consultation with your treating hematologist. Changes in therapy must be guided by a comprehensive clinical review incorporating all laboratory and imaging results.
Exclusion Criteria & Emergency Red Flags
- Exclusion for bone marrow aspiration: active skin or soft tissue infection at planned aspiration site, uncorrected severe coagulopathy (INR > 1.8 or platelets < 20,000/ยตL), or inability to provide informed consent. Minors require legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion for blood draw: severe anemia with hemoglobin below 5 g/dL and hemodynamic instability; phlebotomy deferred until stabilized.
- Emergency red flags after bone marrow biopsy: rapidly expanding hematoma, persistent fever > 38.5ยฐC, severe pain unresponsive to analgesics, or progressive shortness of breath โ seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What does the AML immunophenotyping panel detect?
Flow cytometry immunophenotyping accurately classifies acute myeloid leukemia by detecting CD13, CD33, CD117, and other lineage-defining antigens. It reveals blast percentage, aberrant marker expression, and helps identify targets for targeted therapy. Results direct risk stratification and monitor minimal residual disease post-remission. The panel is designed to differentiate AML from acute lymphoblastic leukemia and mixed-phenotype acute leukemias.
2. How is the sample collected and what should I expect?
A DHA-certified professional collects 2-3 mL of bone marrow aspirate or 5 mL of peripheral blood using strict cold-chain transport. For bone marrow aspiration, local anesthesia is administered at the posterior iliac crest; the procedure takes 10-15 minutes. Samples are maintained at 18-22ยฐC, never refrigerated or frozen, ensuring cell viability. Same-day reporting is delivered if the sample reaches the lab by 9 AM.
3. Is the test available for home collection and what is the total cost?
Hospital extraction only โ the specimen must be collected within an accredited hospital facility; the total package cost is 2,000 AED. The fee covers the hospital-based aspiration procedure, cold-chain transport to our ISO-accredited laboratory, full immunophenotyping analysis, and telephonic post-test clinical guidance. Direct insurance billing can be confirmed via WhatsApp before scheduling. Mobile home phlebotomy is not available for this specimen type due to safety requirements.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient data is processed, stored, and transmitted in full compliance with UAE federal data privacy regulations. Your health information is encrypted and accessed only by authorized medical personnel.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Our digital health systems adhere to the highest standards for electronic health records, telemedicine guidance, and secure cross-platform data exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical procedures โ including bone marrow aspiration and blood draw โ are performed under the legal framework governing medical practice, patient consent, and professional accountability in the UAE.
- DHA Facility License No. 1143: Our Dubai Healthcare City laboratory operates under direct regulatory oversight by the Dubai Health Authority, ensuring compliance with all local diagnostic standards.
Clinical & Logistical Metadata
| Test Name | AML Characterization by Flow Cytometry Immunophenotyping (Leukemia Diagnostic Panel) |
| Price (AED) | 2,000 |
| Turnaround Time | Same-day (sample received by 9 AM) |
| Sample Type / Matrix | Bone Marrow Aspirate (primary), Peripheral Blood (secondary) |
| Methodology Used | 10-Color Multi-Parameter Flow Cytometry Immunophenotyping |
| ICD-10-CM Code | C92.00 (Acute myeloblastic leukemia, not having achieved remission) |
| LOINC Code | 48798-3 (Flow cytometry immunophenotyping interpretation for leukemia/lymphoma panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
โ๏ธ Medical Disclaimer
This test information is for educational purposes only and does not constitute medical advice. Results should be interpreted by a qualified healthcare professional. Always consult with a DHA-licensed physician for diagnosis and treatment decisions.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians